MedPath

University Hospitals Bristol and Weston NHS Foundation Trust

🇬🇧United Kingdom
Ownership
-
Established
1990-01-01
Employees
-
Market Cap
-
Website
https://www.uhbw.nhs.uk/

Clinical Trials

23

Active:1
Completed:15

Trial Phases

5 Phases

Phase 1:1
Phase 2:7
Phase 3:2
+2 more phases

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (20 trials with phase data)• Click on a phase to view related trials

Not Applicable
7 (35.0%)
Phase 2
7 (35.0%)
Phase 4
3 (15.0%)
Phase 3
2 (10.0%)
Phase 1
1 (5.0%)

Acceptance and Commitment Therapy in Tuberous Sclerosis Complex

Not Applicable
Active, not recruiting
Conditions
Tuberous Sclerosis Complex
First Posted Date
2023-05-22
Last Posted Date
2024-02-14
Lead Sponsor
University Hospitals Bristol and Weston NHS Foundation Trust
Target Recruit Count
15
Registration Number
NCT05867576
Locations
🇬🇧

University Hospitals Bristol and Weston NHS Trust, Bristol, United Kingdom

Comparison of Huntleigh Dopplex DMX Digital Doppler Arterial Waveform With the Gold Standard of Ultrasound Duplex Arterial Waveform

Completed
Conditions
Ultrasonography, Doppler
Peripheral Arterial Disease
First Posted Date
2022-05-13
Last Posted Date
2022-07-29
Lead Sponsor
University Hospitals Bristol and Weston NHS Foundation Trust
Target Recruit Count
17
Registration Number
NCT05373875
Locations
🇬🇧

University Hospitals Bristol and Weston NHS Foundation Trust, Bristol, United Kingdom

Newly Diagnosed Immune Thrombocytopenia Testing the Standard Steroid Treatment Against Combined Steroid & Mycophenolate

Phase 3
Completed
Conditions
Immune Thrombocytopenia
Interventions
First Posted Date
2017-05-17
Last Posted Date
2022-10-26
Lead Sponsor
University Hospitals Bristol and Weston NHS Foundation Trust
Target Recruit Count
123
Registration Number
NCT03156452
Locations
🇬🇧

University Hospital Bristol NHS Foundation Trust, Bristol, United Kingdom

A Trial of Cabazitaxel Chemotherapy in Relapsed Locally Advanced &/or Metastatic Carcinoma of the Penis

Phase 2
Completed
Conditions
Penile Neoplasm
Interventions
First Posted Date
2017-04-14
Last Posted Date
2022-11-18
Lead Sponsor
University Hospitals Bristol and Weston NHS Foundation Trust
Target Recruit Count
17
Registration Number
NCT03114254
Locations
🇬🇧

Bristol Haematology and Oncology Centre, Horfield Road, Bristol, United Kingdom

🇬🇧

Universitty College Hospitals NHS Trust, London, United Kingdom

Pilot Study of Cabazitaxel and Paclitaxel in HER2 Negative Breast Cancer

Phase 2
Recruiting
Conditions
HER2 Negative Metastatic Breast Cancer
Interventions
First Posted Date
2017-02-09
Last Posted Date
2019-11-13
Lead Sponsor
University Hospitals Bristol and Weston NHS Foundation Trust
Target Recruit Count
160
Registration Number
NCT03048942
Locations
🇬🇧

Imperial Healthcare NHS Trust, London, Avon, United Kingdom

🇬🇧

Royal United Hospital, Bath, United Kingdom

🇬🇧

Blackpool Victoria Hospital, Blackpool, United Kingdom

and more 10 locations
  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • Next

News

Cemiplimab Plus Chemotherapy Shows Promise in Advanced Penile Cancer EPIC Trial

Phase 2 EPIC trial demonstrates 62.1% clinical benefit rate at 12 weeks for cemiplimab combined with platinum-based chemotherapy in advanced penile carcinoma patients.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.